A method for constructing an animal model of pulmonary hypertension and its application
By using compositions of wild lily and cyanumerine in animal models of pulmonary arterial hypertension, a new rat model of pulmonary arterial hypertension was formed, which solved the problem that the existing models were unable to effectively simulate severe vascular proliferative PAH and clinical severe illness. It achieves simulations that are more suitable for clinical conditions and lower animal mortality, which are suitable for drug screening and right heart failure studies.
Patent Information
- Application Number
- CN202311163262.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-09-08
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-09-08
AI Technical Summary
Existing animal models of pulmonary hypertension, such as wild lily base (MCT) models, cannot effectively simulate pathological and hemodynamic changes in severe vasoproliferative PAH and clinically severe patients, and there are high animal mortality, high economic costs and operation Difficult problem.
Using a composition of wild lily and cyanumerine, a new animal model of pulmonary artery hypertension was formed by administering it in rats. Combined with the evaluation of pathology, cardiac ultrasound and energy metabolism spectrum, it simulates the pathology of PAH and Hemodynamic changes enhance pulmonary smooth muscle hyperplasia and right heart failure, reduce animal mortality, and improve the economics and ease of operation of the model.
This model can better simulate the pathological and hemodynamic changes of PAH, more suitable for the condition of clinically ill patients, and provides an animal model that is more suitable for the study of pulmonary hypertension and right heart failure, suitable for drug screening and potential treatment Target research.
Smart Images

Figure CN117378563B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and in particular relates to a method for constructing an animal model of pulmonary hypertension and an application thereof. Background Art
[0002] Pulmonary arterial hypertension (PAH) is a disease that seriously affects the quality of life and health of human beings. Patients often die from right heart failure. Its pathogenesis is not fully understood. It is currently known to be related to the imbalance of vasoactive substances, immune inflammatory response, gene mutation and non-coding RNA. According to different causes, it is divided into the following five categories: 1) arterial PAH, including idiopathic PAH, hereditary PAH, PAH caused by drugs and toxins, etc.; 2) PAH caused by left heart disease; 3) PAH caused by lung disease and (or) hypoxia; 4) chronic thromboembolic PAH (CTEPH); 5) PAH with unclear and (or) multifactorial mechanisms.
[0003] The most common pulmonary hypertension in adults is caused by left heart disease, followed by lung disease. In children, the most common pulmonary hypertension is related to congenital heart disease, while hereditary or idiopathic pulmonary hypertension is less common but has a poor prognosis. Since the discovery of therapeutic targets at the beginning of this century, there has been no breakthrough in the treatment of pulmonary hypertension in the past 20 years. It is urgently needed to study the hemodynamic changes of pulmonary hypertension through animal models and discover its potential therapeutic targets, especially potential targets or therapeutic genes for improving right heart failure.
[0004] Animal models are helpful in discovering therapeutic targets related to changes in pulmonary circulation hemodynamics and structure. The monocrotaline (MCT) rat model is widely used because of its simplicity and ease of operation. However, MCT also has many problems, such as: 1) The MCT model has limited simulation of severe vascular proliferative PAH, and there are fewer plexiform lesions in pulmonary vascular lesions; 2) MCT model rats usually die from MCT-induced extrapulmonary toxicity and veno-occlusive liver disease, rather than pulmonary hypertension; 3) The MCT model is highly sensitive to drug treatment, and many experimental treatments seem to improve, reverse or prevent MCT-induced pulmonary vascular damage and increased PA pressure, as well as reversible PAH over time. In particular, the last one, the excessive improvement of PAH manifestations in MCT model animals by experimental treatment is often inconsistent with clinical application, so the application of MCT in drug experiments needs to be further determined.
[0005] Animal models of pulmonary hypertension can be roughly divided into two stages. The first stage is nonspecific thickening of the intima and adventitia of the pulmonary artery, mainly including classic models (i.e., hypoxia and MCT). The second stage is the occurrence of plexiform lesions, gradual vascular occlusion, and progressive increase in pulmonary artery pressure, i.e., mixed factor induced modeling. Disease models induced by mixed factors are better correlated with severe human PAH. Since clinical diagnosis is usually severe, mixed factor induced models are more helpful in discovering relevant therapeutic targets for pulmonary circulation hemodynamics and structural changes. However, mixed factors also have defects, such as increased animal mortality, high economic cost of modeling, and difficult operation in a hypoxic environment.
[0006] Therefore, a method for constructing a pulmonary hypertension model that can better simulate the pathological and hemodynamic changes of PAH, is more in line with the condition of critically ill patients, and can make up for the shortcomings of the classic MCT model has practical significance. Summary of the invention
[0007] The first aspect of the present invention aims to provide a composition.
[0008] The second aspect of the present invention aims to provide the application of the above composition.
[0009] The third aspect of the present invention aims to provide a product.
[0010] The fourth aspect of the present invention aims to provide a method for constructing an animal model of pulmonary hypertension.
[0011] The fifth aspect of the present invention aims to provide an application of the pulmonary hypertension animal model obtained by the above-mentioned construction method.
[0012] The sixth aspect of the present invention aims to provide a method for screening drugs for treating pulmonary arterial hypertension.
[0013] The technical solution adopted by the present invention is:
[0014] The first aspect of the present invention provides a composition comprising monocrotaline and fenvalerate.
[0015] Preferably, the dosage of monocrotaline is 50-70 mg / kg bw.
[0016] Preferably, the concentration of monocrotaline is 0.5-1.5%.
[0017] Preferably, the fenvalerate is administered at a dosage of 10-20 mg / kg bw.
[0018] Preferably, the concentration of fenvalerate is 10-20 mg / ml.
[0019] The second aspect of the present invention provides use of the composition described in the first aspect of the present invention in constructing an animal model of pulmonary hypertension or preparing a product for constructing an animal model of pulmonary hypertension.
[0020] Preferably, the animal comprises a rodent.
[0021] Preferably, the rodent comprises a rat.
[0022] The third aspect of the present invention provides a product, wherein the product comprises the composition described in the first aspect of the present invention.
[0023] Preferably, the product is used to construct an animal model of pulmonary hypertension.
[0024] Preferably, the product is a reagent, feed, or medicine.
[0025] Preferably, the product further comprises any other ingredients. For example, when preparing feed for constructing an animal model of pulmonary hypertension, ordinary animal feed is also added to the composition. When preparing drugs for constructing an animal model of pulmonary hypertension, conventional solvents, adhesives, solubilizers, preservatives and other auxiliary materials are added to the composition according to the preparation of different medicaments to prepare tablets, capsules, granules and oral liquids.
[0026] In a fourth aspect, the present invention provides a method for constructing an animal model of pulmonary hypertension, comprising constructing an animal model using the composition described in the first aspect of the present invention or the product used in the second aspect of the present invention.
[0027] Preferably, the construction method comprises the following steps: administering monocrotaline to animals on the first day of modeling, administering cypermethrin to animals every day for at least 14 days before the modeling stage, and culturing for more than 30 days to obtain an animal model of pulmonary hypertension.
[0028] Preferably, in the construction method, fenvalerate is administered to the animals daily during the first 14 to 25 days of the modeling period.
[0029] Preferably, in the construction method, the pulmonary hypertension animal model is obtained by culturing for more than 30 to 45 days.
[0030] Preferably, the dosage of monocrotaline is 50-70 mg / kg bw.
[0031] Preferably, the concentration of monocrotaline is 0.5-1.5%.
[0032] Preferably, the monocrotaline is administered by injection.
[0033] Preferably, the injection administration comprises subcutaneous injection administration.
[0034] Preferably, the fenvalerate is administered at a dosage of 10-20 mg / kg bw.
[0035] Preferably, the concentration of fenvalerate is 10-20 mg / ml.
[0036] Preferably, the fenvalerate is administered by intragastric administration.
[0037] Preferably, the fenvalerate is prepared using corn oil as a solvent.
[0038] Preferably, the animal comprises a rodent.
[0039] Preferably, the rodent comprises a rat.
[0040] Preferably, the rat weighs 200-220 g.
[0041] Preferably, the rat is male.
[0042] Preferably, the strain of the rat is SD rat, Wistar rat or Lewis rat.
[0043] The fifth aspect of the present invention provides the use of an animal model of pulmonary hypertension constructed by the method described in the fourth aspect of the present invention in studying the molecular mechanism of the occurrence and development of pulmonary hypertension, or in preparing and / or screening drugs for preventing and / or treating pulmonary hypertension, or in preparing products for evaluating the therapeutic effect of pulmonary hypertension.
[0044] A sixth aspect of the present invention provides a method for screening a drug for treating pulmonary arterial hypertension, comprising:
[0045] (1) An animal model of pulmonary hypertension constructed by the method described in the fourth aspect of the present invention;
[0046] (2) administering the candidate drug to the pulmonary hypertension animal model established in step (1);
[0047] (3) Using the degree of damage improvement in the pulmonary hypertension animal model to evaluate and screen the candidate drugs for treating pulmonary hypertension.
[0048] The beneficial effects of the present invention are:
[0049] The present invention develops a new pulmonary hypertension rat model with energy metabolism changes by co-intervention of monocrotaline and cypermethrin; the difference between the model and the classic MCT model is jointly evaluated by combining pathology, cardiac ultrasound and energy metabolism spectrum changes, and the changes in the gene transcriptome level of the model are analyzed, and the related mechanisms are explored; the results show that the animal model can better simulate the pathological and hemodynamic changes of PAH, is more in line with the condition of clinical critically ill patients, and significantly improves the previous shortcomings of monocrotaline by introducing cypermethrin, enhances pulmonary artery smooth muscle hyperplasia, aggravates right heart failure, and does not significantly increase mortality; provides a pulmonary hypertension animal model that better simulates the pathological and hemodynamic changes of PAH; is of great significance for clinical research on pulmonary hypertension; is particularly suitable for the study of right ventricular metabolic disorders or potential right heart failure genes, and is expected to make new contributions to the study of pulmonary hypertension; and provides a research basis for the screening of related drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0050] Figure 1 The present invention is a method for constructing an animal model of pulmonary hypertension.
[0051] Figure 2 The results of body weight, right heart remodeling, pulmonary artery pressure and left heart function examination were analyzed.
[0052] Figure 3 HE staining and immunofluorescence staining were used to detect rat lung tissue.
[0053] Figure 4 Immunofluorescence of mitochondrial function in rat right ventricle.
[0054] Figure 5 Immunofluorescence of the Golgi apparatus function in rat right ventricle.
[0055] Figure 6 Immunofluorescence of rat right ventricular macrophage function.
[0056] Figure 7 The top 20 KEGG pathways enriched for KEGG differential analysis of left ventricle mRNA between NT and MCT rats.
[0057] Figure 8 The top 20 KEGG pathways enriched in KEGG differential analysis of left ventricle mRNA between NT and MCT+Fen rats.
[0058] Fig. 9 The top 20 KEGG pathways enriched for KEGG differential analysis of right ventricle mRNA between NT and MCT rats.
[0059] Fig.10 The top 20 KEGG pathways enriched in KEGG differential analysis of right ventricle mRNA between NT and MCT+Fen rats.
[0060] Fig.11 The top 20 KEGG pathways enriched in KEGG differential analysis of left ventricle mRNA in MCT and MCT+Fen rats.
[0061] Fig.12 The top 20 KEGG pathways enriched in the KEGG differential analysis of right ventricle mRNA in MCT and MCT+Fen rats.
[0062] Fig.13 Specific detection results of the top 20 KEGG pathways enriched in the KEGG differential analysis of right ventricle mRNA in MCT and MCT+Fen rats.
[0063] Fig.14 For the analysis of rat right ventricular metabolism. DETAILED DESCRIPTION
[0064] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.
[0065] Example 1
[0066] 1. 40 male SD rats of 6-8 weeks old and weighing approximately 200-220g were selected (female rats were avoided because they interfere with the secretion of estrogen) and randomly divided into 4 groups, 10 rats in each group. That is: control group, MCT group, Fen group, MCT+Fen combined group. The rat breeding conditions are: ambient temperature of 20-22℃; ambient humidity of about 50%; light intensity should be about 25lux; it is a normal environment for rat breeding, without special restrictions.
[0067] MCT was dissolved in 1mmol / L dilute hydrochloric acid, then adjusted to pH 7.4 with 1mmol / L sodium bicarbonate, and finally diluted with saline to a 1% monocrotaline solution. On the first day of the experiment, the drug was administered subcutaneously via the back of the neck at a dose of 60mg / kg in a volume of 0.1-0.2ml.
[0068] Fen was dissolved in corn oil and shaken to prepare a 15 mg / ml cypermethrin solution. It was administered orally every day for the first 14 days of the experiment at a dose of 15 mg / kg bw.
[0069] Animal construction steps see Figure 1 .
[0070] 2. Animal Handling
[0071] After 5 weeks of feeding, the rats were anesthetized and skin was prepared, and the left and right heart functions were examined by small animal cardiac ultrasound. The rats were killed under conventional anesthesia, and serum, heart, and lung tissues were taken for further testing.
[0072] 3. Experimental methods
[0073] The rats were weighed, and the weight of the left ventricle + ventricular septum and the weight of the right ventricle free wall were weighed respectively.
[0074] Paraffin sections were prepared from perfusion-fixed lung tissue and right ventricular tissue and immunofluorescence analysis was performed.
[0075] The right ventricular tissue was collected and stored in liquid nitrogen for mRNA and energy metabolomics analysis.
[0076] 4. Experimental results
[0077] 1) The combined treatment group aggravated right heart failure and right heart remodeling
[0078] After 5 weeks of feeding, the body weight was measured and it was found that the body weight of rats in the MCT group was significantly lower than that in the NT group, but the body weight of the MCT+Fen group recovered compared with the MCT group. Combined with the results of subsequent experiments, it was considered that the weight gain was caused by right heart failure edema rather than improvement. Previous articles often used the Fulton Index to evaluate the right ventricular mass and indirectly evaluate the right heart remodeling. It was found that the Fulton Index of the MCT+Fen group was further increased than that of the MCT group, indicating that the right heart weight increased and the right heart remodeling worsened.
[0079] Color Doppler ultrasound examination of small animals revealed that compared with the MCT group, the pulmonary artery pressure in the MCT+Fen group did not increase further. In recent years, guidelines do not use pulmonary artery pressure alone to assess the severity of lung disease (see Guidelines for the diagnosis and treatment of pulmonary hypertension). Although the left ventricular diastolic diameter did not decrease significantly in the MCT group compared with the NT group, the diameter of the left ventricle in the MCT+Fen group was significantly smaller than that in the NT group, indicating that the right heart in the MCT+Fen group was more significantly enlarged, compressing the left heart and causing the left heart diastolic diameter to decrease. The heart rate of the compensatory MCT+Fen group was higher than that of the MCT group. Although the heart rate was adjusted to the same level as much as possible ( Figure 2 ).
[0080] 2) The combined treatment group aggravated pulmonary smooth muscle hyperplasia
[0081] Typical pathological changes of pulmonary hypertension include: 1) intimal thickening and fibrosis, forming an "onion skin"-like structure; 2) medial thickening, smooth muscle cell hyperplasia and hypertrophy; 3) branching and expansion of thin-walled muscular arteries, presenting vascular plexus-like lesions. HE staining revealed that the pulmonary artery smooth muscle in the MCT+Fen group proliferated more significantly than that in the simple MCT group, which was consistent with the aforementioned description of increased Fulton index, right heart remodeling, and worsening of the overall condition.
[0082] Further immunofluorescence staining was used to specifically mark smooth muscle cells with a-SMA antibodies, indicating that the width of a-SMA in the MCT+Fen group was significantly increased compared with that in the MCT alone group, indicating that the MCT+Fen group had more obvious pulmonary artery smooth muscle hyperplasia ( Figure 3 ).
[0083] 3) The combined treatment group aggravated the damage of right ventricular myocardial mitochondria and Golgi
[0084] By immunofluorescence detection of mitochondria and Golgi bodies in the right ventricular myocardium, it was found that compared with the simple MCT group, the expression of mitochondria and Golgi bodies in the MCT+Fen group was model-lower than that in the NT group or the simple MCT group, indicating that the MCT+Fen group would aggravate mitochondrial autophagy. It was also found that in the Mertk and CD68 immunofluorescence of the right ventricle, the MCT+Fen group increased the number of CD68. Therefore, the analysis of the MCT+Fen group significantly increased the autophagy of the right ventricular myocardium, and the mitochondria engulfed and decomposed by the autophagosome were recognized by Mertk and processed by macrophages ( Figure 4-Figure 6 ).
[0085] 4) Effects of combined treatment group on right ventricular myocardial mRNA
[0086] This embodiment detects mRNA in the left ventricle and right ventricle. This study found that compared with the NT group, there were many differential genes in both the simple MCT and MCT+Fen groups, but there was no statistical difference in the mRNA of the left ventricle between the MCT+Fen group and the MCT group. Simply analyzing the right ventricular mRNA found that there was a significant statistical difference in the mRNA between the MCT+Fen group and the MCT group. In short, the MCT+Fen treatment group was verified by immunofluorescence technology to more significantly inhibit mitochondrial and Golgi function, leading to mitochondrial dysfunction and aggravating the Warburg reaction. The aggravation of this reaction means the aggravation of heart failure.
[0087] In order to verify this conclusion, we analyzed at the mRNA level and found that the MCT+Fen group had greater interference with oxidative phosphorylation, diabetic cardiomyopathy, and tricarboxylic acid cycle pathways than the simple MCT group. Further metabolomics analysis confirmed that the metabolic effects of the MCT+Fen group on the right ventricle were mainly concentrated in the tricarboxylic acid cycle and carbon metabolism. Therefore, MCT+Fen treatment had a more obvious interference with right ventricular metabolism, resulting in more severe right heart failure in pulmonary hypertension, which is a more suitable animal model for exploring potential targets for the treatment of right heart failure ( Figure 7-Figure 14 ).
[0088] In summary, the new rat pulmonary hypertension model developed by the present invention aggravates pulmonary artery smooth muscle hyperplasia and right ventricular myocardial remodeling, and has more obvious interference with right ventricular metabolism than the existing single-factor model, resulting in more severe right heart failure caused by pulmonary hypertension. It is more economical than the existing multi-factor model, does not significantly increase the mortality rate, is easier to operate, and does not require additional equipment.
[0089] The above specific implementations have been described in detail for the present invention, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.
Claims
1. A method for constructing an animal model of pulmonary hypertension, comprising constructing the animal model using monocrotaline and cypermethrin; The construction method The following steps are involved: Monocrotaline was administered to the animals on the first day of modeling, and cypermethrin was administered to the animals every day for at least 14 days before the modeling stage, and the animal model of pulmonary hypertension was obtained after culturing for more than 30 days; The dosage of monocrotaline is 50-70 mg / kg bw, and the dosage of fenvalerate is 10-20 mg / kg bw; The concentration of monocrotaline is 0.5-1.5%; The concentration of fenvalerate is 10-20 mg / mL; The administration method of monocrotaline is injection; The administration method of cypermethrin is intragastric administration.
2. The construction method according to claim 1, It is characterized in that The animals include rodents.
3. The construction method according to claim 2, It is characterized in that The rodents include rats.
4. Use of the pulmonary hypertension animal model constructed by the method according to any one of claims 1 to 3 in studying the molecular mechanism of the occurrence and development of pulmonary hypertension, or in preparing and / or screening drugs for preventing and / or treating pulmonary hypertension, or in preparing products for evaluating the therapeutic effect of pulmonary hypertension.
5. A step of screening a drug for treating pulmonary hypertension, include: (1) An animal model of pulmonary hypertension constructed by the method described in any one of claims 1 to 3; (2) administering the candidate drug to the pulmonary hypertension animal model established in step (1); (3) Using the degree of damage improvement in the pulmonary hypertension animal model to evaluate and screen the candidate drugs for treating pulmonary hypertension.
